TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Market Perform and lowers the price target from $32 to $30.
TD Cowen Maintains Market Perform on PTC Therapeutics, Lowers Price Target to $30
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.